People

Gabrielle Girouard, PhD, serves as an Investment Analyst at Theodorus, where she evaluates and supports early- to growth-stage life science and biotech ventures. Prior to joining Theodorus, she was a fellow with HaloHealth, a Canadian physician- and dentist-led angel investment group, gaining experience in health-tech investing. With a PhD in Biomedical Sciences focused on vascular retinopathies from the Université de Montréal (Canada), Gabrielle brings domain expertise in ophthalmology and vascular biology. Theodorus publishes Gabrielle Girouard with the following specifically scoped affiliation: Investment Analyst (published Theodorus platform team; Fund IV-specific appointment not independently dated). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Tomoko holds a PhD in Biology with extensive research experience in cancer biology and immunology, bringing a unique scientific perspective to venture capital. Currently an Executive MBA candidate at Chicago Booth, Tomoko combines deep technical expertise with strategic business acumen to drive value for both startups and investors. Having lived in seven countries across four continents, Tomoko offers a global perspective, adept at navigating diverse markets and identifying opportunities for disruptive innovation in biotech and healthcare worldwide.

Pierre Detrixhe is Managing Partner at Financière spin-off luxembourgeoise and Venture Director at Newton Biocapital. He brings more than 10 years of experience in the field of venture capital and has accompanied many companies in the start-up phase. Previously, he held positions of scientist and technology transfer officer in the biotechnology field. Pierre Detrixhe is Director at the Board of some promising Belgian start-up companies. He holds a Master in Bioengineering from the University of Liège (Gembloux Agro-Bio Tech), Belgium and a Master in Management from the Catholic University of Louvain, Belgium. He brings more than 10 years of experience in the field of venture capital and has accompanied many companies in the start-up phase. Previously, he held positions of scientist and technology transfer officer in the biotechnology field. Pierre is Director of the Board of promising start-ups including Apaxen, ATB Therapeutics, Becarv, Bioxodes and Synergia Medical. He holds a Master in Bioengineering from the University of Liège (Gembloux Agro-Bio Tech) and a Master in Management from the Catholic University of Louvain, Belgium. Based in Belgium LinkedIn Newton Biocapital publicly documents this person as Venture Director. The affiliation is scoped to the published role, with no personal cash investment inferred. Pierre Detrixhe is publicly named by ORSA Fund (formerly Investsud) as Investment Manager. The institution provides long-term equity and quasi-equity financing to Walloon companies across industry, biotechnology and innovative technology; this affiliation is an operating role. Bioxodes affiliation: Pierre Detrixhe is Managing Partner at Financière spin-off luxembourgeoise and Venture Director at Newton Biocapital. He brings more than 10 years of experience in the field of venture capital and has accompanied many companies in the start-up phase. Previously, he held positions of scientist and technology transfer officer in the biotechnology field. Pierre Detrixhe is Director at the Board of some promising Belgian start-up companies. He holds a Master in Bioengineering from the University of Liège (Gembloux Agro-Bio Tech), Belgium and a Master in Management from the Catholic University of Louvain, Belgium.

Christina Franssen, PhD, currently an Investment Manager at WE Life Sciences, brings over two decades of experience in innovation and research to her role. Prior to joining WE Life Sciences in 2019, Christina served as Business Development Manager and later Director of State-of-the-Art Technology Platforms at GIGA, a research institute associated with the University of Liège. Christina started her career as a research scientist and went through the full cycle of entrepreneurship, founding a spin-off company, and leading it to a successful exit. She holds a Master’s degree in Biology and a PhD in Microbiology & Genetics from the Université de Liège (Belgium). Christina Franssen is an investment manager in the published Q4 2024 WE Life Sciences roster since 2019, formerly GIGA technology-platform director and business-development manager. Founded DNAVision AgriFood and holds microbiology/genetics doctoral and biology degrees from the University of Liège. Current NEUVASQ issuer biography corroborates WE affiliation. Registered Christine name is not treated as a proven legal alias without further evidence. The dated public roster does not by itself establish a new employment start day or uninterrupted tenure through October 2026.

Michel Allé, a civil engineer with a master’s degree in economics, has held various managerial positions throughout his career. He has been a manager at the Belgian Science Policy Office, served as a member of the Management Committee of Cobepa (formerly a subsidiary of Paribas), and worked as the CFO of both Brussels Airport and the Belgian Railways. Michel’s academic accomplishments include serving as a professor at the Solvay Brussels School of Economics and Management, where he was also the president from 1997 to 2001. Michel has been the Chairman of the Board of Ogeda and currently holds director positions at the D’Ieteren Group and Elia Group (both listed), and serves as the Chairman of the Board of Epics Therapeutics.

Areas of Expertise Clinical Ophthalmology Additional Institutions/Organizations American Academy of Ophthalmology / Société Française d’Ophtalmologie Country Belgium

Dr. rer. physiol. Areas of Expertise Neuro-immunology and brain barriers Additional Institutions/Organizations International Brain Barrier Society Vice-President/ President Country Switzerland

Areas of Expertise Stroke, Genetics, Cerebral Small Vessel Disease Country Germany

Areas of Expertise Blood brain barrier, Blood-retina barrier, tight junctions Additional Institutions/Organizations Trinity College Institute of Neuroscience (TCIN) PI, FutureNeuro Centre PI and executive board member, Vice-Chair Sight Research UK SAB, member of the SAB of Moorfields Eye Hospital Charity Country Ireland

Professor Benoit Vanhollebeke, PhD, is a molecular biologist at the Université libre de Bruxelles (ULB) and a senior investigator at the WEL Research Institute. His research trajectory spans from elucidating immune evasion strategies of African trypanosomes to pioneering investigations into the development and maintenance of the brain vasculature. His laboratory identified the Gpr124/Reck signaling complex, establishing its mechanism of action and clarifying its role as a critical regulator of brain angiogenesis and the blood–brain barrier. His team further demonstrated the feasibility of its selective activation, thereby validating the Gpr124/Reck complex as a transformative therapeutic target for repairing the blood–CNS barriers in neurological and cerebrovascular disorders. Professor Vanhollebeke’s work has appeared in leading journals including Science , Nature , the New England Journal of Medicine (NEJM) , PNAS , Nature Medicine , Nature Communications , Nature Microbiology , Nature Cardiovascular Research , Cell Reports , Brain , and eLife . This research has yielded multiple patents and is now being translated into therapeutic applications through Neuvasq Biotechnologies. His scientific leadership has been recognized with European Research Council (ERC) and WEL Research Institute funding, along with several honors, including the recent FNRS Triennial Prize of the Pierre & Simone Clerdent Foundation for research in human neurological disorders, and the Fondation Lambertine Lacroix Prize for contributions to cardiovascular disease research.

PhD, Chief Scientific Officer Ralph has an extensive experience in developing drugs in the central nervous system (CNS). He was previously CSO of Lysogene, a French biotech specialized in gene therapy targeting CNS diseases. Prior to this, he was Senior Vice President and Head of Discovery and Product Development at Teva Pharmaceutical Industries in Israel. Prior to Teva, he was the Scientific Director of IRBM, an Italian drug discovery CRO. Previously, Ralph was Head of Pharmacology at Merck Research Laboratories Rome. Ralph obtained his PhD in Biochemistry (summa cum laude) and M.Sc. in Chemistry from the Hebrew University of Jerusalem. He conducted postdoctoral training at the Institut Pasteur in Paris, and is the author of close to 100 scientific articles and an inventor on about 30 patents.

Denis Bedoret currently serves as Executive Director of Neuvasq Biotechnologies. He is also Director in the Boards of Ncardia, BePharBel, and previously Exothera. Prior to taking its new role at Neuvasq, Denis was Chief Executive Officer at Imcyse, a clinical-stage biopharmaceutical company committed to advancing the development of a new class of specific immunotherapies to treat auto-immune diseases. Prior to this, he was the CEO of MaSTherCell SA, Belgium and President of MaSTherCell Global Inc., U.S. Under his leadership, the Company expanded significantly growing from 60 to 260 employees and positioning as a leader in the field of CDMO’s dedicated to Cell and Gene therapies products before being acquired by Catalent. Denis also held the position of Chief Operations Officer at Quality Assistance S.A. a leading European analytical CRO where he was also a member of the Board of Directors. Before that, Denis served as engagement manager at McKinsey & Company, focusing on life science projects.

Karim joined Novo Holdings as an Associate in March 2022. He participates in sourcing, execution and portfolio management of private equity & venture capital investments. Prior to joining Novo Holdings, Karim worked at Nordic Investment Opportunities where he invested in alternatives across private equity, infrastructure, real estate and private credit. Subsequently, Karim worked for Goldman Sachs in London where he gained experience within asset management. Besides Karim’s experience as an investment professional, he worked as a Teaching Assistant in Advanced Statistics at the University of Copenhagen. Karim holds a MSc in Economics and Finance from the University of Copenhagen and has completed coursework at the London School of Economics and Harvard University.

Junie joined Novo Ventures (US) Inc., in 2016 in San Francisco, CA, as US General Counsel. She helps to manage investment structuring and negotiation, portfolio company management, regulatory governance, and other general legal matters. Prior to joining Novo, Junie was Counsel at Wilson Sonsini Goodrich & Rosati where she represented private and public biotech and technology companies and venture capital firms in financings, mergers and acquisitions, corporate governance, recapitalizations and other stock related matters, complex contract negotiations, securities compliance and disclosures, employment issues, intellectual property issues, and strategic partnerships. Junie holds a Juris Doctor from New York University School of Law, New York, New York, and a B.A. in Economics from Smith College, Northampton, Massachusetts.

Karthik Narayanaswamy joined Novo Holdings in January 2025 as Partner and Head of India, bringing over 20 years of experience in private equity investing, strategy consulting, and operations. Before joining Novo Holdings, Karthik was the Co-founder and Partner at SeaLink Capital Partners, a mid-market private equity firm focused on India, where he led the firm’s healthcare investments. Prior to that, he served as a Principal at KKR Capstone, where he oversaw due diligence and drove operational improvements across KKR's investments in India. Karthik’s earlier career includes his time at Bain & Company, where he was a founding member of the India office. During his tenure, he specialized in private equity due diligence and performance improvement. He also gained investment experience at Goldman Sachs Investment Partners and began his career at Capital One Financial in Richmond, Virginia. Karthik holds a Bachelor of Technology in Computer Science and Engineering from the Indian Institute of Technology (IIT) Bombay.

Julie joined Novo Holdings A/S in June 2024 as Senior Legal Counsel and takes part in handling all legal matters within the company, including in particular investments and divestments, corporate law and general contract matters. Prior to joining Novo Holdings A/S, Julie worked as a senior associate in the M&A department of Accura law firm, specializing in M&A and general corporate law. Prior to joining Accura, Julie has been working for almost 10 years with Plesner law firm and as a foreign visiting associate at the law firm Holland & Knight in New York.  Julie holds a Master of Laws from the University of Copenhagen (2013) and a LL.M. from Columbia Law School (2018). She is admitted to the Danish Bar (2017) and the New York Bar (2019).

Julian Homburger joined Novo Holdings in 2024 as an Associate on the Ventures team and is based in San Francisco. Prior to joining Novo Holdings, Julian was an Associate Director at Foresite Labs, where he led translational research to support the creation and launch of new companies in healthcare and biotechnology. Julian has held multiple roles at the intersection of life science and data science, including at Color Health and at Maze Therapeutics. Julian holds a PhD in Genetics from Stanford University, where he published multiple studies in cardiovascular genetics and human population genomics. He also holds a BS in Statistics from Cornell University.

Jon joined Novo Principal Investments in September 2020 as a Senior Partner, to further the team’s presence in the United States. He brings over 10 years of healthcare private equity experience as well as several years as an investment banker. Most recently, Jon served as a Managing Director in the healthcare team at CVC Capital Partners based in New York. Prior to joining CVC, he worked at private equity firms LetterOne Health and Tailwind Capital Partners as well as the investment bank Lazard. Jon has a BA in Ethics, Politics and Economics from Yale University and an MBA from Columbia Business School.

After 9 years in clinical and academic medicine in Denmark and in the United States, Jørgen spent 18 years in R&D Executive positions in Denmark, Switzerland, United States, France and Germany. Jørgen co-founded and built the Nasdaq-listed biotech company Zealand Pharma ( ZEAL.CO ), held senior leadership at Lundbeck and Novo Nordisk, and as SVP at Merck he established the Immunology franchise. He has industrial R&D experience across multiple therapeutic areas, including CNS, cardiovascular disease, diabetes, oncology and autoimmune disease, and has been involved in a number of major pharmaceutical licensing deals and alliances. Jørgen serves on the board of Acesion Pharma, Engimmune Therapeutics, Breye Therapeutics, Hemab Therapeutics, AnaCardio, Antag Therapeutics, and RheumaLogics. Jørgen holds MD, PhD, and DMSc degrees from the University of Copenhagen and an MBA degree from the Technical University of Denmark.

Johan Hueffer joined Novo Holdings A/S as Senior Director in Principal Investments in August 2019. Johan spent almost 15 years at Morgan Stanley in London, starting his career in the healthcare team. While at Morgan Stanley, he also worked in M&A and Princes Gate Investors, a Morgan Stanley-sponsored private equity fund. Subsequently, Johan co-founded Pangea Investors, a private equity firm focused on mid-market European companies. Johan holds a BA from Harvard College and an MBA from Harvard Business School. He is a Dutch national.

Jonas joined Novo Holdings A/S in December 2015 as Associate General Counsel and takes part in handling all legal matters within the company, including in particular investments and divestments, corporate law and general contract matters. Prior to joining Novo Holdings A/S, Jonas was employed with Danske Bank A/S for two years where he was globally responsible for the legal aspects of the bank’s corporate finance activities in the Nordics, the UK and the US. During the eight years before that, Jonas worked as senior associate in the M&A and capital markets group at the law firm Plesner in Copenhagen and as foreign lawyer in the corporate finance group at the law firm Reed Smith in New York. As a result, Jonas has obtained significant experience with respect to Danish, Nordic and international M&A, capital markets and financing transactions. Jonas holds a Master of Laws from the University of Copenhagen (2005) and an LL.M. with honors from Columbia Law School (2010) with focus on corporate finance, securities regulation and M&A. He is a member of the Danish Bar Association

Johan joined Novo Holdings in April 2008 as Investment Manager in Capital Investments. Johan holds a MSc in Finance from Copenhagen Business School, Denmark. Prior to joining Novo Holdings Johan was employed at Scandium Asset Management and Finansbanken.

Johan joined Novo Holdings A/S in October 2026 as a Senior Procurement Specialist in Finance & Operation. Prior to joining Novo Holdings A/S, Johan worked at Ørsted, initially as a procurement specialist consequently heading a team of procurement specialists. Previously Johan worked in Maersk Drilling in various commercial functions, including three years in Houston, Texas. Johan holds a Master degree in International Marketing and Management from Copenhagen Business School.

Joel Koh joined Novo Holdings Asia in July 2023 as an associate. Prior to joining Novo Holdings, Joel was an Investment Banking Analyst from Houlihan Lokey. Joel also brings Healthcare investment experience from his internship with Novo Holdings Asia. He also has experience as an investment intern at Partners Group, Apollo Glob al Management Inc. and Everstone Group. Joel holds a Bachelor of Business (Banking and Finance) from Nanyang Technological University of Singapore, Nanyang Business School.

About Joanne Burns US citizen Board positions Joanne is an experienced board professional and currently serves on the boards of ATI Physical Therapy, Availity, and SNOMED International. Career 2021 – Board of Directors, ATI Physical Therapy 2020 – Board of Directors, Availity 2007 – Chair Of the Board Of Directors, SNOMED 2019 – 2023 Board of Directors, Innara Health 2013 – 2019 Chief Strategy Officer, Cerner Corporation 2010 – 2013 CIO and VP, Executive Director, University of Missouri   Health Care, Tiger Institute for Health Innovation 2007 – 2010 Vice President, Product Development, Cerner Corporation 2004 – 2007 Director, Product Development, Cerner Corporation 1998 – 2003 Director of Information Technology, Stanford University Medical Center 1988 – 1998 Clinical Nurse, Stanford University Medical Center Education Joanne holds a Registered Nursing Degree from the State University of New York at Plattsburgh, a Master’s degree in Health Services Administration from the University of San Francisco, and a ‘Women on Boards’ Program Certification from Harvard T.H. Chan School of Public Health.

Joe is joining from Boston Consulting Group, where he worked with healthcare and private equity clients on strategy, portfolio planning, and due diligence projects. Prior to BCG, Joe was a postdoctoral fellow at the California Institute of Technology, where he used synthetic biology tools and mathematical modeling to study morphogen gradients. Joe holds a PhD in Biophysics from Harvard University, where he studied circadian clocks.  He also holds an MPhil in Chemistry from Cambridge University, where he was a Gates Scholar, and an AB in Biochemical Sciences from Harvard.

Joachim joined Novo Holdings in September 2020 as Associate in Capital Investments, where he is responsible for analyzing direct investment opportunities. During his studies, Joachim worked in Finance Denmark gaining experience with macroeconomic analyses as well as in Novo Holdings’ Financial Investment team. Joachim holds a BSc in Economics and an MSc in Economics from University of Copenhagen.

Jill joined Principal Investments in 2017 as Coordinator. Prior to joining Novo, Jill was employed at Novo Nordisk A/S for more than 15 years in various administrative roles within Global Development. Jill holds a Bachelor of Commerce in Strategic Management and Project Management.

About Joachim Kreuzburg German citizen Board positions In addition to his numerous board positions and directorships within the Sartorius Group, Joachim serves as member of the Supervisory Board of Carl Zeiss AG, member of the Administrative Board of Ottobock Management SE, member of the Senate of Max Planck Gesellschaft, and member of the Executive Board of Stifterverband für die Deutsche Wissenschaft. Career highlights 2007–2025     Chairman, Sartorius Stedim Biotech S.A., France 2003–2025     CEO and Executive Board Chairman, Sartorius AG 2002–2003     CFO and Member of the Executive Board, Sartorius AG 1999–2002      Various positions at Sartorius AG, Germany, including as Vice President, Finance and Investor Relations 1995–1999       Research Associate, Faculty of Economics and Management, University of Hannover, Germany 1992–1995       Research Associate, Lower Saxony Institute for Solar Energy Research, Hameln, Germany Education Joachim holds a doctorate (Dr. rer. pol.) in Economics as well as a Masters degree (Dipl.-Ing.) in Mechanical Engineering, both from the University of Hannover.

Career highlights 2025–               Co-Managing Partner, Multiplier 2021–2025      Director, US Department of Energy Loan Programs Office 2013–2021       Co-Founder and President, Generate Capital 2009–2012      Founding CEO, Carbon War Room 2003–2008     Founding CEO, SunEdison LLC 2000–2003     Business Development, BP Solar 1997–1999       Analyst, Energetics Education Jigar holds an MBA in Finance and Strategy from the University of Maryland as well as a BSc in Mechanical Engineering from the University of Illinois Urbana-Champaign.

Jessica joined Novo Holdings in 2023 in Principal Investments. She participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments. Prior to joining Novo Holdings, Jessica was an Associate on the healthcare team at KKR, where she worked on private equity and growth equity investments. She began her career in the investment banking division of J.P. Morgan. Jessica holds a BS in Computer Science and in Management with a minor in Economics from the Massachusetts Institute of Technology and an MBA from Harvard Business School.

Jessica is Senior Associate in the Venture Investments team at Novo Holdings, based in San Francisco. Before joining Novo Holdings, she worked as an analyst in the Healthcare Investment Banking Group at Lazard, where she focused on strategic M&A, licensing deals, and a wide scope of advisory work for biotech, pharmaceuticals, tools, and diagnostics companies. Jessica holds a dual degree in Bioengineering and Economics (Honors) from the University of California, Berkeley.

Jessie joined Novo Holdings Asia in September 2023 as Senior Legal Counsel. Prior to joining Novo Holdings, Jessie worked at Fosun International for five and a half years as Executive Legal Director, responsible for legal matters relating to overseas investments as well as daily operations of the health division of Fosun International. Prior to joining Fosun International, Jessie worked at Shanghai offices of K&L Gates, DLA Piper and boutique law firms for ten years focusing on M&A, private equity and corporate law. Jessie holds an LL.M. (Master of Laws) from University of California, Berkeley and an LL.B. (Bachelor of Laws) from Shanghai Jiao Tong University. Jessie is admitted to New York Bar and PRC Bar.

Jenny Lou is listed by Novo Holdings as Senior Associate in Venture Investments. Further biography is not published on the reviewed profile.

Jeroen Bakker, PhD, is a Partner at Novo Holdings Seed Investments. He has over a decade of biotech investment experience, driving investment processes and portfolio management for companies like Adcendo, Antag Therapeutics and Rappta Therapeutics (licensed to Springworks Therapeutics). He’s currently driving Novo Holdings new €188m investment strategy around quantum which aims to invest in companies and funds that are utilizing quantum tech to impact human and planetary health. Prior to joining Novo Seeds, Jeroen was an Associate at M Ventures, the corporate venture capital arm of Merck, where he was responsible for sourcing, due diligence and gained board exposure for a variety of Seed and Series A investments across Europe, United States Israel. Jeroen also received operational experience through a number of roles in Syntaxin (acquired by Ipsen), Inthera and ISD Immunotech. Prior to joining biotech, he was a Research Fellow at the La Jolla Institute for Allergy and Immunology in San Diego. Jeroen holds a PhD in Immunology from the University of Amsterdam, a MSc in Biomedical Sciences from the Leiden University with a specialization in entrepreneurship and a BSc from the Technical University of Delft. Jeroen was chair of the Dutch Platform for Young Researchers in Nephrology, served on the board of BiOrigin, a Novo Holdings-backed entrepreneur-in-residence subsidiary and a member of REBBLS, a Danish networking organization focusing on young biotech entrepreneurs.

Jeppe Kolding joined Novo Holdings in 2025 as a Vice President in the Planetary Health Investments team. Before joining Novo Holdings, Jeppe served as a Vice President in the Life Sciences team at Moelis & Company, initially based in London and later in San Francisco, where he focused on M&A in the biopharma sector. Prior to that, he worked in the M&A team at Ernst & Young, starting in the Copenhagen office as a sector generalist before relocating to London, where he covered the life sciences sector across EMEIA. Jeppe holds a MSc in Finance & Accounting and a BSc in Economics & Business Administration from Copenhagen Business School.

Jennifer joined the People & Organisation team in 2019 and is based in the San Francisco office. As Head of HR for the US offices of Novo Holdings, she is responsible for driving the company’s talent management and HR strategies. Before joining Novo Holdings, Jennifer served as Senior HR and Operations Manager at PureTech Health, where she oversaw HR operations, employee relations, and recruitment initiatives. Prior to that, she held various roles in finance and administration at Harvard University and Marriott. Jennifer received a graduate certificate in Human Resources Management from Cornell University.

Jean-Christophe Fonfreyde is listed by Novo Holdings as Executive Director, Head of Total Rewards in Strategy and People. Further biography is not published on the reviewed profile.

Jeffers is an Executive Assistant in the Venture Investments team at Novo Holdings, based in San Francisco. Jeffers completed his Bachelor of Arts degree from San Francisco State University. Prior to joining Novo Holdings, he was a full-time student and previously worked at Dell Technologies as an inside sales representative.

Jan joined Novo Holdings A/S in December 2018 as Senior Specialist in Finance & Operations where he joined the F&O team. In March 2024, Jan transferred to NH P&O, Total rewards and Operations. In P&O, Jan kept parts of his work portfolio from F&O including global salary and bonus controlling, the car policy and FTE management and Budget. Jan is working on various projects such as establishment of the NH office in India and the establishment of the AIFM as well as having a role in the management of the LTIP program. Prior to joining Novo Holdings A/S Jan was employed by Zebra A/S (Flying Tiger Copenhagen) where he was part of the Group Finance as Senior Financial Controller for more than 3 years. Prior to this Jan spent 2½ years with Dako (Agilent Technologies) as Head of Financial reporting and Tax as his last position. Prior to this Jan has been working as Financial Controller for various companies such as MSC, Coloplast, Danisco and Maersk. Jan holds a MSc in Business Administration and Commercial Law (Cand.Merc.Jur) from Aarhus Business School.

Board positions In his capacity as global healthcare advisor, Jean-Luc has served on numerous boards and committees, including the Singapore Economic Development Board (EDB), the National Medical Research Council (NMRC) and Singapore’s Accelerate (ASTAR). He currently serves on the boards of several prominent organisations, such as Rani Therapeutics, ICON Group, Takeda Pharmaceutical, Jana Care and Singapore Agency for Science Technology and Research (A*STAR), where he is on the board of the DxD Hub and Chair of the Investment Committee. Between 2017-2024, Jean-Luc was a Board member at Novo Holdings, and since then he has served on the Novo Advisory Group. Career 2015 – 2015     President – International, Baxter International, Singapore 2012 – 2014     Corporate Officer; Operating Committee Member; Corporate Vice President; President – International, Baxter International, US 2011 – 2012       Corporate Officer; Executive Committee Member; Executive Vice President; Group President – International, Medtronic, Singapore 2008 – 2010     Group President – International, Medtronic, Japan 2003 – 2008    Corporate Officer; Executive Committee Member; Senior Vice President, Medtronic; President, Medtronic Asia Pacific, Japan 1991 – 1999       Various positions (General Manager, Microbiology, Nippon; President, Nippon; Vice President, Consumer Healthcare, North America; Corporate Officer, President, Worldwide Consumer Healthcare), Becton Dickinson, Japan & US 1990 – 1991      Marketing Director, Johnson & Johnson Medical - Singapore, Indonesia, Malaysia, Singapore 1988 – 1990      China Project Manager, Johnson & Johnson International, Hong Kong 1985 – 1988     General Manager, Johnson & Johnson, Fiji Education Jean-Luc holds a BA in International Affairs from The George Washington University, and an MBA in International Management from the American Graduate School of International Management.

Jacob joined Novo Holdings in August 2020 as Partner in Capital Investments. Jacob holds a MSc in Finance and Strategic Management from Copenhagen Business School and an CEMS MIM degree from Copenhagen Business School and University of Cologne. Prior to joining Novo Holdings Jacob was employed at PFA Pension, PKA AIP and Macquarie Capital.

Jacob joined Novo Holdings in March 2021 as an Associate in Capital Investments. He participates in deal sourcing and execution, as well as in managing the existing portfolio. Prior to joining Novo Holdings, Jacob gained experience from real estate private equity at NREP where he worked with direct investments. He also has experience from Novo Nordisk Consulting. Jacob holds a MSc in Advanced Economics and Finance and a BSc in International Business from Copenhagen Business School.

Jacob joined Novo Holdings A/S in January 2025 as a Senior Automation Specialist. As part of the Digital team, Jacob is responsible for automating complex business solutions throughout the company. Before Novo Holdings, Jacob gained experience from Zibra A/S where he was tasked with assisting the portfolio companies with digital automation and as a Senior Consultant in Finance IT Services in Basico P/S. Jacob holds a BA in History from The New School, and an MA in European Studies from the King’s College London.

Jacob Gadensgaard is listed by Novo Holdings as Associate in Planetary Health Investments. Further biography is not published on the reviewed profile.

Ishan joined Novo Holdings Equity US in July 2021 in Principal investments. He evaluates, executes and manages investments across the healthcare sector and is based in our Boston office. Ishan has been involved in healthcare principal investing and advisory since 2014. Prior to Novo Holdings Equity US, he served as a private equity investment professional at Linden Capital Partners and Sterling Partners. Ishan was also part of the founding management team of Healthwell Acquisition Corp. I. He began his career in the healthcare investment banking group at Jefferies. Ishan holds a BBA in Finance from Emory University.

Isobel Crabb is an Associate in the Planetary Health Investments team. She joined Novo Holdings in July 2025. Prior to this, she was a Senior Consultant at Globe Life Sciences, advising life sciences companies and investors on commercial strategy, asset evaluation, and market analysis. She began her career in healthcare-focused equity research and sales, covering a broad range of subsectors across the healthcare industry. Isobel holds a degree in Natural Sciences from the University of Cambridge.

Hulbert Soh joined Novo Holdings Asia in October 2022 as a Senior Associate. Prior to joining Novo Holdings Asia, Hulbert was a Global Healthcare Investments Associate Director from SeaTown Holdings International (Subsidiary of Temasek Holdings). He also brings Healthcare investment experience from MyoKardia (Subsidiary of Bristol-Myers Squibb), Verily Life Sciences and Lazard Frères & Co. Hulbert started out at Credit Suisse as an Investment Banking Analyst, Biotechnolgy coverage. Hulbert completed the Roy and Diana Vagelos Program in Life Sciences and Management (LSM) at University of Pennsylvania and holds a Bachelor of Art in Chemistry as well as a Bachelor of Science in Economics , Concentration in Finance from The Wharton School.

Henrik joined Novo Holdings in August 2017, where he is currently Head of Valuation within the Finance & Operations department. In this role, he overseas and leads the valuation processes, providing support to investment and leadership teams in all valuation matters. Prior to joining Novo Holdings, Henrik spent 5 years at Deloitte Financial Advisory, where he gained comprehensive knowledge of valuation and financial modeling. Before his tenure at Deloitte, Henrik worked as a Financial Analyst at DONG Energy and as an Analyst at Lind Capital. He holds an M.Sc. in Finance from Aarhus School of Business, Aarhus University.

Henrik joined Novo Holdings in January 2022 as Strategy Associate. Prior to joining Novo Holdings, Henrik worked at Monitor Deloitte, Copenhagen. During his time with Monitor he worked on a range of different strategy projects predominantly advising global pharmaceutical companies. Henrik holds a MSc in Finance and Strategic Management and a BSc in International Business from Copenhagen Business School.

Henrik joined Novo Holdings A/S in December 2017 as a Senior Director, Principal Investments, leading investment process and taking part in managing and developing the growing portfolio of investments. Prior to joining Novo Holdings A/S, Henrik was employed as a Senior Vice President in Moelis & Co. in London, focusing on healthcare buy-and sell-side M&A transactions. Other previous employments include Deutsche Bank and ABN AMRO all in London. Henrik holds a BSc. in Business Administration and an MSc. in Applied Economic and Finance from the Copenhagen Business School.

Helle Bach joined Novo Holdings in 2025 as Chief People Officer. She is part of the Strategy & People organisation and a member of the Executive Leadership Team. In her role, Helle will be heading up the People & Organisation area across offices in Denmark, the US, London and APAC.  Before joining Novo Holdings, Helle headed up the global HR function at DSV A/S, where she was responsible for building up the Group HR function, and participated in large and transformative company M&A’s. Prior to this, Helle worked for Egmont International Holding, also heading up the people area, and in her early career, she worked as a management consultant for Rambøll Management.  Helle holds a Master of Political Science degree from Aarhus University (2001).

Helen joined Novo Holdings A/S in October 2018 in Principal Investments. She participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments. Prior to joining Novo Holdings A/S, Helen worked as an investment professional with the private equity firm OpCapita in London. During this time, she worked actively with existing portfolio companies as well as assessing new acquisition opportunities across Europe. Before this, Helen worked as a mergers and acquisitions generalist at Moelis & Company in London. Helen holds an MBA from Copenhagen Business School and a BA degree in Natural Sciences from the University of Cambridge.

Heather is responsible for controlling the venture investments from a financial and administrative perspective. Prior to joining Novo A/S in 2003, Heather spent seven years with Brown Brothers Harriman & Co., first as head of the European Internal Audit function based in Luxembourg and then as the Investment Management Business Line Controller based in New York City. Prior to this, Heather was an Audit Manager and CPA with PricewaterhouseCoopers in both Luxembourg and Boston. Heather holds a BS in Accounting and a BA in Business Administration from the University of Kansas.

Helga joined Novo Holdings A/S in August 2025 as Senior Legal Counsel, Competition Lawyer. She advises on a broad range of competition law matters, including merger control, foreign direct investment filings, and general compliance with competition law. Before joining Novo Holdings, Helga was a Senior Associate in the competition law practice at Clifford Chance in Belgium. She also practiced competition law at Van Bael & Bellis law firm in Brussels. Helga holds a Master of International Law from the United Nations-mandated University for Peace, a Magister Juris from the University of Iceland, and an LL.M. from Harvard Law School. She is admitted to practice law as a member of the Icelandic Bar Association.

Hans-Christian Sune Andersen is listed by Novo Holdings as Head of Reporting & Controlling in Finance & Operations. Further biography is not published on the reviewed profile.

Gábor Gyülvészi is listed by Novo Holdings as Principal in Seed Investments. Further biography is not published on the reviewed profile.

Gloria joined Novo Holdings in 2023 as the Office Manager for Shanghai.  Prior to joining Novo Holdings, she was an Office Manager with Robeco Private Fund Management (Shanghai). Gloria has operational and office management experience at Onion Capital LLP, BlackRock Overseas Investment Fund Management (Shanghai) Co., Ltd. and Greenhill Cogent Shanghai Representative Office.

Gareth joined Novo Holdings in 2024 as ESG Manager in the Responsible Investments team. Prior to joining Novo Holdings, Gareth was Sustainable Finance Programme Manage at Ørsted. Gareth brings 10 years of Corporate Sustainability experience through previous employment at Pandora, Maersk, and consulting. Gareth holds an MSc in Environment and Natural Resource Economics from Copenhagen University, Denmark from 2015.

Gaia-Emilie joined Novo Holdings A/S in April 2024 as a Data Engineer. She is supporting the development and architecture of Novo Holding's Data Platform and advanced analytics capabilities. Prior to joining Novo Holdings A/S, Gaia-Emilie worked at Valcon as a Data Engineering Consultant. There, her focus was Data Orchestration and development of Data Platforms, primarily within Business Intelligence,  Machine Learning, and Artificial Intelligence. Gaia holds a MSc in Economics and Business Administration from Copenhagen Business School.

Frederik joined Novo Holdings in May 2021 as an Associate in Capital Investments. He is responsible for analyzing direct investment opportunities in the credit markets and managing partnerships with external managers. Prior to joining Novo Holdings, Frederik gained experience from Investment Banking and Equity Research at SEB. Frederik holds a MSc in Finance and Strategic Management and a BSc in International Business from Copenhagen Business School.

Frederik joined Novo Holdings A/S in November 2017 as a Specialist in Finance & Operations. He manages the investment management applications used by Novo Holdings. Prior to joining Novo Holdings, Frederik was employed for 2 years at SimCorp A/S, where he was part of the ASP team – Application Service Providers – managing the operation and hosting of customers’ SimCorp Dimension solution. Before that he worked in PwC as a Consultant specialized in data analysis, and in FIH Erhvervsbank A/S – a Danish bank – as an analyst. Frederik holds an MSc in Business Administration and Management Science.

Member of the Novo Holdings Board since 2017. Francis Cuss was born in 1954 and is a dual national of both the United Kingdom and the United States. He received a BA in Natural Sciences, MB, BChir and MA from Cambridge University. He is a Fellow of the Royal College of Physicians and of the Faculty of Pharmaceutical Medicine. Francis Cuss began his career in clinical medicine and research in the United Kingdom. Francis Cuss has over 35 years of clinical experience across the pharmaceutical industry. In 1986, he started at GlaxoSmithKline plc (then Glaxo Inc.), UK and United States, as a Director in Pulmonary Clinical Research. From 1989, Francis Cuss worked at the Schering-Plough Research Institute where he held several positions in Discovery and Development, eventually becoming Senior Vice President of Early Clinical Research & Experimental Medicine. Francis Cuss joined Bristol-Myers Squibb Research & Development in 2003, first working as Senior Vice President of Discovery and later as Senior Vice President for all of Research and Early Development. In 2010, he joined the company’s senior management team. In 2013, he was appointed Executive Vice President, Chief Scientific Officer and Head of Research & Development at Bristol-Myers Squibb Company, retiring in 2017. Other Board Positions and Management Duties: Trustee for Montclair State University in New Jersey, United States External Advisor at Editas Medicine, Cambridge MA, United States

Francie is a Principal in the Venture Investments team at Novo Holdings, based in San Francisco.  Prior to joining Novo Holdings, Francie was an associate at Incentrum Group, a New York City-based merchant bank, where she focused on investing and advising in the healthcare, life and material science, and technology industries. Prior to Incentrum, Francie was an analyst in the Healthcare Investment Banking Group at Bank of America Merrill Lynch where she worked on a variety of strategic and financing transactions across the healthcare services, medical technology, and life science sectors. Francie holds a BSc in Mathematical Business from Wake Forest University.

Erik Torres is a Global IT Business Relationship Specialist, based in the San Francisco office. Prior to Novo Holdings, Erik worked as a Global Operations Manager at EOS IT Solutions, Erik oversaw IT logistics and managed a team of associates across global locations, focusing on process optimization, stakeholder relations, and achieving KPIs and SLAs. Before that, he worked as a Project Coordinator and Operations Analyst, identifying operational improvements and enhancing departmental performance.   Erik has a B.S. in Computer Science from San Francisco State University.

Eva Ammitzbøll Rasmussen joined Novo Holdings A/S as Executive Assistant in Principal Investments in June 2025. Eva brings broad experience in executive and personal assistance, having supported senior leadership at Altor Equity Partners and Thylander in roles such as Executive Assistant, Personal Assistant, and Office Manager. She holds professional qualifications in HR & Employment Law, Legal Secretary Training, Event Management, and Coordination. With strong organizational skills, a proactive mindset, and a service-oriented approach, Eva is dedicated to ensuring smooth and efficient executive support. Fluent in Danish, English, and German, she combines structure and flexibility in a way that adds tangible value to any leadership team.

Emmanuelle joined Novo Holdings A/S in September 2015 and is Partner at Seed Investments. She led several investment rounds and company creation efforts and serves on the Boards of several companies. Emmanuelle has more than 15 years of experience in venture capital investment. Prior joining Novo Seeds, Emmanuelle was Partner Life Sciences at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium and The Netherlands. Emmanuelle obtained her MSc degree from the Agrocampus Ouest (France) in 2003 and her PhD degree in 2006 from the Paris 7 University, for her work on the immunosuppressive properties of a bacterial toxin, conducted at Pasteur Institute (Paris, France). She also has a Specialized Master in pharmaceutical management from ESCP-EAP. She led several investment rounds and company creation efforts, and serves on the Boards of Corwave, Aloop, MinervaX, Draupnir, Heparegenix and BiOrigin.Emmanuelle has more than 15 years of experience in venture capital investment. Prior joining Novo Seeds, Emmanuelle was Partner Life Sciences at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium and The Netherlands. Emmanuelle obtained her MSc degree from the Agrocampus Ouest (France) in 2003 and her PhD degree in 2006 from the Paris 7 University, for her work on the immunosuppressive properties of a bacterial toxin, conducted at Pasteur Institute (Paris, France). She also has a Specialized Master in pharmaceutical management from ESCP-EAP.

Eric joined Venture Investments (US) Inc. in March, 2018. Previously, Eric was a managing director for Navigant Consulting, a strategic consulting firm supporting life science companies and investors, based in New York. Before joining Navigant, he worked as a management consultant for McKinsey and Leerink Partners Consulting, as well as in the global market analytics team at Pfizer with a focus on business development. Eric earned a PhD in Neuroscience from Brown University and conducted post-doctoral studies at the Fisher Center for Alzheimer’s Disease at Rockefeller University.

Emil Christensen is listed by Novo Holdings as Director in Finance & Operations. Further biography is not published on the reviewed profile.

Emily joined Novo Holdings in 2024 as an Associate in the Principal Investments group. She participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments. Prior to joining Novo Holdings, Emily was an Investment Banking Analyst on the healthcare team at Morgan Stanley. Emily holds a BA in Molecular and Cell Biology and a BS in Business Administration from UC Berkeley .

Emilie joined Novo Holdings A/S as Executive Assistant to Nigel Govett, Chief Financial Officer. Prior to joining Novo Holdings A/S, Emilie worked at the BioInnovation Institute Foundation (BII) as Senior Personal Assistant from 2022-2024, and before that Emilie worked at Novo Holdings A/S as Board Assistant from 2019-2022. From 2011-2019, prior to BII and Novo Holdings A/S, Emilie has been employed in Novo Nordisk A/S in various administrative roles within Marketing, Medical Affairs, Communications and Executive Offices in both Copenhagen and Zürich, providing senior management support and coordination of meetings and events.

Ellen is the Head of Compliance and Operational Risk (U.S.) at Novo Holdings, based in the Boston office. She joined Novo Holdings in April 2026 and brings over a decade of experience in regulatory compliance across the asset management and private equity industries. Prior to joining Novo Holdings, Ellen served as Head of Regulatory Compliance at Arrowstreet Capital, where she oversaw the firm’s core compliance functions. Before Arrowstreet, she spent four and a half years at Aberdeen with her latest role being the Chief Compliance Officer of the U.S. Private Equity division. Earlier in her career, Ellen worked at Bain Capital, leading the firm’s regulatory filings function. Ellen began her career as an auditor at PricewaterhouseCoopers LLP, where she focused on the asset management industry. She holds a Master of Science in Accounting from Suffolk University and a Bachelor of Science in Accounting from the Isenberg School of Management at the University of Massachusetts Amherst.

Elle Metzger joined the Novo Holdings Boston office in 2025 as Senior Legal Counsel. Prior to joining Novo, Elle served as legal counsel at Boston Consulting Group, where she supported M&A and strategic transaction initiatives. Prior to that, Elle was an Associate at Goodwin where her work focused on an array of private company transactions, including complex US and cross-border growth equity investments, mergers, acquisitions, leveraged buyouts, direct secondary and private company liquidity programs, as well as general corporate matters. Elle holds a J.D. from Boston College Law School, and a B.A. in Political Science from the University of Notre Dame.

Elena is an Associate in the Venture Investments team at Novo Holdings, based in San Francisco. Prior to joining Novo Holdings, she was a private equity associate at H.I.G. Capital, where she worked on investments across a broad range of sectors. Before H.I.G., Elena was an investment banking analyst in the technology group at Bank of America. Elena holds a B.S. in Finance and Statistics from the Wharton School and an M.S.E. in Data Science from the University of Pennsylvania.

Board positions Peter currently serves as Chairperson of the Board at Harpe Bio, Senior Advisor at SVG Ventures, and Operational Partner at Astanor Ventures. Career 2024 – Senior Advisor, SVG Ventures I THRIVE 2024 – Chairperson of the Board, Harpe Bio 2024 – Operational Partner, Astanor Ventures 2015 – 2023        President and CTO, BASF Agricultural Solution 2009 – 2015        President and CEO, BASF Plant Science 2002 – 2009       Senior Vice President, BASF Agricultural Solution 2000 – 2002       Vice President New Business Development Chemicals, BASF 1996 – 1999         Production Manager, BASF 1994 – 1996         Head of R&D Staff to CTO, BASF 1992 – 1994         Research Chemist, BASF Education Peter holds a PhD in Organic Chemistry from Goethe University of Frankfurt.

Consultant to CEO Royal DSM Former President of DSM China, Group VP Former President of Novozymes China, Group VP

Board and advisory positions 2024 -               Board Member, Livasa Hospitals, India 2025 -               Advisor, EQT Group, India 2021 – 2022     National Health Authority, India 2020 – 2021     Advisory Board Member, GenomSys, Switzerland Career 2021 -                Co-Founder & CEO, NeuranceAI Technologies, India 2025 -               Independent Director, NephroPlus, India 2019 – 2021      Co-Founder & CEO, BuddhiMed Technologies 2018 – 2019     CEO, Parkway Pantai Ltd. 2014 – 2017     Managing Director & CEO, Manipal Hospitals 2011 – 2014      CEO, Max Healthcare Education Ajay holds an MBBS in Medicine & Surgery as well as an MCh in Neurosurgery from the All India Institute of Medical Sciences. In addition to this, he has a Certificate in Management, Business from the Wharton School.

Chairman, Synthace Board member, WCG Former CEO and Exec Chair, WCG Served as Operating Partner and Co-Head of the Healthcare Group at Arsenal Capital Partners

Dorthe joined Novo Holdings in August 2022 as a valuation specialist in Finance & Operations. She participates in valuation and performance measurement activities. This includes quarterly fair market value assessments of the portfolio companies as well as valuation and modelling support to the investment teams. Prior to joining Novo Holdings, Dorthe held a position at Danica Pension, where she was responsible for carrying out valuations of Danica’s portfolio of alternative investments. Prior to this, Dorthe worked as a consultant in PwC’s Deals team for two years, where she obtained comprehensive knowledge within valuation and financial modelling. Dorthe holds a MSc in Finance & Accounting from Copenhagen Business School

Chief Executive Officer, Tecan (2012-Mar 2019) Non-executive director, BÜCHI Labortechnik AG (2016-2018) Non-executive Chairman, Sphere Medical Holding plc (2015-2018)

Dora joined the US team in May 2023 as Public Relations Specialist supporting both Novo Holdings and Novo Nordisk Foundation. Prior to joining the team, Dora served as Communications Administrator for a department in the MIT School of Engineering. Earlier she worked in investor relations and public relations in a Boston-based agency. Before that, she was a business journalist for Grupo Reforma. Dora holds an MA in Communication Management from Emerson College, and a BA in Journalism and Media Studies from Tec de Monterrey.

Divya joined Novo Holdings Asia in November 2024 as a Senior Associate. Prior to joining Novo Holdings, Divya was an Associate Vice President with HealthQuad – an Indian Healthcare Transformation Fund. During her 6 year tenure with the firm, she worked on numerous healthcare, health-tech and life sciences investments in India and was actively involved across deal evaluation and execution, portfolio monitoring, exits and fund raising. She has also previously worked with Goldman Sachs India as an Investment Analyst. She holds an MBA (Finance & Marketing) from Management Development Institute (MDI), Gurgaon and a Bachelor’s Degree in Chemical Engineering from the Institute of Chemical Technology (ICT), Mumbai.

Doheon joined Novo Holdings in 2024. Prior to joining Novo Holdings, Doheon worked at Mubadala's Direct Investments team in Abu Dhabi, where he covered Korea and Japan markets as well as transacted the firm's various buyouts and monetization efforts globally. Before this, he spent 5 years in the investment banking division at Morgan Stanley Hong Kong where he worked across a broad range of M&A and Capital Markets transactions. Doheon holds a BSc in Business (summa cum laude) with Concentrations in Finance and Statistics from NYU Stern School of Business.

Dominic Lee joined Novo Holdings Asia in July 2026 as an Associate. Prior to joining Novo Holdings, Dominic was an Investment Banking Analyst with UBS AG where he worked on ECM and M&A transactions across sectors. He brings over two years of experience with exposure to deal execution, financial modelling and investor engagement. He holds a Degree in Business Management (Finance Major) from Singapore Management University.

Deepa joined Novo Holdings Asia in April 2024 as Partner for Asia in the Planetary Health Investments team. She manages and develops the Bio-Industrial investment portfolio across Asia. Prior to joining Novo Holdings, Deepa was heading Asia activities for IFU, an Investment Fund owned by the Danish Government, investing public and private capital, on commercial terms, creating positive impact in emerging markets.   Deepa has 25+ years of investment experience in Asia and has led several greenfield and growth stage investments across multiple sectors, including Climate (renewable energy, energy efficiency, circularity, water), Agri business and infrastructure, Financial Services, Manufacturing and Healthcare. Deepa holds a Masters in Finance from University of Delhi, India and an E*MBA from SIMI (now under Copenhagen Business School), Denmark.

Danni joined Novo Holdings A/S in 2023 as Senior Legal Counsel and handles various legal matters pertaining to the company, including in relation to investments and divestments as well as general corporate and commercial law matters. Prior to joining Novo Holdings A/S, Danni was a corporate associate in the New York and Hong Kong offices of Davis Polk and the Hong Kong offices of Gibson Dunn, where she represented corporates, financial institutions and private equity sponsors on a variety of M&A and capital markets transactions. Danni holds a J.D. from Columbia Law School and a B.A. in Political Science from Duke University. She is a member of the New York bar.

Danielle joined Novo Ventures (US) Inc. in 2020 as Associate General Counsel.  Prior to joining Novo, Danielle was an Associate at Goodwin Procter where she represented private equity sponsors, and their portfolio companies, in a variety of transactions, including venture capital financings, growth equity investments, mergers, acquisitions, leveraged buyouts, recapitalizations and general corporate and securities matters.  Prior to joining Goodwin, Danielle was an Associate at CamberView Partners, where she advised management and boards of directors of public companies on productive investor engagement, focusing on matters relating to corporate governance, executive compensation, environmental, social and governance and contested mergers and acquisitions. Danielle holds a J.D. from the University of Southern California, Gould School of Law, and a B.A. in Political Science and Spanish from the University of California, Berkeley.

Daniel Rasmussen joined Novo Holdings in 2024 as a Principal in Seed Investments. He is responsible for fund investments across biotechnology and quantum technology. Daniel has extensive experience in venture capital and growth equity. At BASF Venture Capital, he led and supported investments in frontier technologies, including quantum technology. Previously, he was with Verdane, a leading growth equity investor, where he focused on scaling technology companies across Northern Europe. He began his career at Oaklins as a corporate finance advisor, working on mid-market M&A transactions. He holds an MSc in Finance & Accounting and a BSc in Economics and Business Administration from Copenhagen Business School.